Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol plus methotrexate versus adalimumab plus methotrexate in adults with rheumatoid arthritis inadequately responding to methotrexate
2011-002067-20Phase 4Completed
- Sponsor
- UCB
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in rheumatoid arthritis (RA) comparing Certolizumab pegol plus methotrexate with Adalimumab plus methotrexate (2 arms). Primary endpoints: Percentage of subjects meeting ACR20 criteria and Week 12 prediction of Week 104 treatment success. Started Feb 2012; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-002067-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002067-20.